188 related articles for article (PubMed ID: 37539052)
1. An optimized cultivation method for future
Bold A; Gross H; Holzmann E; Knop S; Hoeres T; Wilhelm M
Front Immunol; 2023; 14():1185564. PubMed ID: 37539052
[TBL] [Abstract][Full Text] [Related]
2. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
3. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
4. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
5. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
[TBL] [Abstract][Full Text] [Related]
6. Bioengineering and serum free expansion of blood-derived γδ T cells.
Sutton KS; Dasgupta A; McCarty D; Doering CB; Spencer HT
Cytotherapy; 2016 Jul; 18(7):881-92. PubMed ID: 27260209
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
Inoue Y; Oda A; Maeda Y; Sumitani R; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Jun; 119(6):626-630. PubMed ID: 38581458
[TBL] [Abstract][Full Text] [Related]
8. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.
Nussbaumer O; Gruenbacher G; Gander H; Thurnher M
Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342
[TBL] [Abstract][Full Text] [Related]
9. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells.
Ko Y; Jeong YH; Lee JA
Cells; 2022 Jul; 11(14):. PubMed ID: 35883606
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
12. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
[TBL] [Abstract][Full Text] [Related]
13. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
[TBL] [Abstract][Full Text] [Related]
15. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
16. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
[TBL] [Abstract][Full Text] [Related]
17. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
19. Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8
Chen HC; Joalland N; Bridgeman JS; Alchami FS; Jarry U; Khan MWA; Piggott L; Shanneik Y; Li J; Herold MJ; Herrmann T; Price DA; Gallimore AM; Clarkson RW; Scotet E; Moser B; Eberl M
Immunol Cell Biol; 2017 Aug; 95(7):620-629. PubMed ID: 28356569
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
